var data={"title":"Haemophilus influenzae type b conjugate vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Haemophilus influenzae type b conjugate vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6299?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=haemophilus-influenzae-type-b-conjugate-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Haemophilus influenzae type b conjugate vaccine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=haemophilus-influenzae-type-b-conjugate-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Haemophilus influenzae type b conjugate vaccine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178251\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ActHIB;</li>\n      <li>Hiberix;</li>\n      <li>PedvaxHIB</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178252\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ActHIB;</li>\n      <li>Hiberix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178262\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13361407\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immunization:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults who have not received the childhood Hib series <b>and</b> are at increased risk for invasive Hib disease due to sickle cell disease, anatomic/functional asplenia or splenectomy. ACIP recommendations: One dose (0.5 mL); may use any of the Hib conjugate vaccines (CDC/ACIP [Briere 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults who are recipients of a successful hematopoietic stem cell transplant: Revaccinate with a 3-dose regimen beginning 6-12 months after the transplant, regardless of vaccination history. Doses should be administered &ge;4 weeks apart (CDC/ACIP [Briere 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178258\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=haemophilus-influenzae-type-b-conjugate-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Haemophilus influenzae type b conjugate vaccine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization (CDC/ACIP [Briere 2014]): Note:</b> The number of doses for completion of Hib series is dependent upon products including some combination formulations (3 doses: ActHIB, Hiberix; 2 doses: PedvaxHIB) (see combination product monographs for specific dosing information)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 6 weeks to 6 months: Minimum age for first dose is 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ActHIB, Hiberix (PRP-T): IM: 0.5 mL per dose for a total of 3 doses administered as follows: 2, 4, and 6 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PedvaxHIB (PRP-OMP): IM: 0.5 mL per dose for a total of 2 doses administered as follows: 2 and 4 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ActHIB, Hiberix: Children 15 to 18 months: IM: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PedvaxHIB: Children 12 to 15 months: IM: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ACIP recommendation: Children 12 to 15 months: IM: 0.5 mL as a single dose (CDC/ACIP [Briere 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization of older patients at risk: </b> Children &ge;5 years and Adolescents who have not received the childhood Hib series <b>and</b> are at increased risk for invasive Hib disease due to HIV infection, anatomic/functional asplenia or splenectomy, immunoglobulin deficiency, early component complement deficiency, or chemotherapy or radiation therapy. ACIP recommendations: One dose (0.5 mL); may use any of the Hib conjugate vaccines (CDC/ACIP [Briere 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Repeat immunization for high-risk conditions (CDC/ACIP [Briere 2014):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invasive Hib disease: Infants and Children &lt;24 months: Revaccinate with a second primary series beginning 4 weeks after onset of disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Undergoing chemotherapy or radiation therapy: Infants and Children &lt;60 months: If dose administered within 14 days of starting or given during therapy: Repeat the vaccine doses at least 3 months after therapy completion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematopoietic stem cell transplant recipient: Children and Adolescents: Revaccinate with a 3-dose regimen beginning 6 to 12 months after successful transplant, regardless of vaccination history. Doses should be administered &ge;4 weeks apart.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897418\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897419\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178235\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ActHIB: <i>Haemophilus</i> b capsular polysaccharide 10 mcg [bound to tetanus toxoid 24 mcg] per 0.5 mL [contains sucrose; may be reconstituted with provided diluent (forms solution)] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hiberix: <i>Haemophilus</i> b capsular polysaccharide 10 mcg [bound to tetanus toxoid 25 mcg] per 0.5 mL [contains lactose 12.6 mg]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PedvaxHIB: <i>Haemophilus</i> b capsular polysaccharide 7.5 mcg [bound to <i>Neisseria meningitidis</i> OMPC 125 mcg] per 0.5 mL (0.5 mL) [contains aluminum; natural rubber/natural latex in packaging]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178221\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734115\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hib.html&amp;token=mjmpv7xMHRIW2nr+3NCnsUZAizKE5q1N5Y6YVyHCDVdnyLqA1hHjDCLQugB0t1TFg6m6umAEqL0gl8X5zAMhYQ==&amp;TOPIC_ID=8511\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hib.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178238\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: For IM administration; do not inject IV, intradermally, or subcutaneously. Shake well prior to use. Administer into the anterolateral thigh or deltoid. Do not administer into buttocks due to potential risk of injury to sciatic nerve. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ActHIB, PedvaxHIB: If the primary series is delayed or interrupted, there is no need to start the series over, regardless of the interval between doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hiberix: If Hiberix is inadvertently administered during the primary vaccination series, the dose can be counted as a valid PRP-T dose that does not need to be repeated if administered according to schedule. In this case, a total of 3 doses completes the primary series (CDC 58[36] 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178236\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Active immunization for the prevention of invasive disease caused by <i>Haemophilus influenzae</i> type b (Hib):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ActHIB: Immunization of infants and children 2 months to 5 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hiberix: Immunization of infants and children 6 weeks to 4 years of age (prior to fifth birthday).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PedvaxHIB: Routine vaccination of infants and children 2 to 71 months of age. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for the following (CDC/ACIP [Briere 2014]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Routine immunization of all infants and children through age 59 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Unimmunized (defined as those who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age) children 12 to 59 months including chemotherapy recipients, anatomic or functional asplenia (including sickle cell disease), HIV infection, immunoglobulin deficiency or early component complement deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efficacy data are not available for use in older children and adults with chronic conditions associated with an increased risk of Hib disease. However, use may be considered for:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Unimmunized (defined as those who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age) children &ge;5 years, adolescents and adults with functional or anatomic asplenia, (including sickle cell disease)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Unimmunized (defined as those who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age) children &ge;5 years and adolescents with HIV infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Children &lt;5 years undergoing chemotherapy or radiation treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Successful hematopoietic stem cell transplant recipients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Children &ge;15 months and adolescents undergoing elective splenectomy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49748540\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hib (<i>haemophilus</i> b conjugate vaccine) may be confused with HepB (hepatitis B vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hib (<i>haemophilus</i> b conjugate vaccine) may be confused with HPV (human papillomavirus vaccine; 2vHPV, 4vHPV, or 9vHPV are the correct abbreviations)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178228\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (infants: 67% to 76%; children: 13% to 27%), drowsiness (infants: 49% to 66%; adults: 60%; children: 13% to 36%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (infants: 28% to 33%; children: 6% to 13%), diarrhea (booster dose in children: 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (infants: 43% to 57%; children: 21%), erythema at injection site (infants: 19% to 32%; children: &lt;1%), swelling at injection site (infants: 13% to 22%; children: &le;4%), tenderness at injection site (&le;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1% to 35%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (children: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Induration (children: &le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Guillain-Barr&eacute; syndrome, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site: soreness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Tracheitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abscess at injection site (sterile), anaphylactoid reaction, anaphylaxis, angioedema, apnea, febrile seizures, hypersensitivity reaction, hypotonic/hyporesponsive episode, lymphadenopathy, peripheral edema, pneumonia, pruritus, swelling of extremities, swelling of the injected limb (extensive), syncope, vasodepressor syncope, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178241\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to <i>Haemophilus</i> b polysaccharide, tetanus toxoid-containing vaccine (Hiberix and ActHIB only), or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178225\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome (GBS): ActHIB, Hiberix: Use with caution in patients with history of GBS; carefully consider risks and benefits to vaccination in patients known to have experienced GBS within 6 weeks following previous tetanus-containing vaccination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tetanus immunization: Immunization with ActHIB or Hiberix does not substitute for routine tetanus immunization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of Hib containing combination vaccines in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable. According to the ACIP, monovalent Hib vaccines are interchangeable; however, if different brands are used in the primary series and the number of doses required for series completion varies, then the higher number of doses is recommended for series completion (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination (ACIP [Kroger 2017]). In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines). Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Some products may contain lactose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]). Infection may occur within the week of vaccination, prior to the onset of the vaccine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299433\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178229\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8511&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178232\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178244\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570862\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administration does not affect the safety of breastfeeding for the mother or the infant (ACIP [Kroger 2017]). Breastfeeding also appears to reduce the incidence of infant fever associated with routine childhood immunization (Piscane 2010). Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13908724\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178224\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates production of anticapsular antibodies and provides active immunity to <i>Haemophilus influenzae</i> type b. Vaccination provides protective antibodies in &gt;95% of infants who are vaccinated with a 2- or 3-dose series (CDC 2012). An anti-PRP concentration of &ge;1.0 mcg/mL predicts long-term protection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25306341\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immunity develops progressively with each dose.  Immunity can be inferred ~ 2 weeks after the initial series is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Efficacy: The initial unconjugated polysaccharide Hib vaccines produced 45% to 88% reduction in disease incidence among children at least 18 to 24 months of age. The initial protein-conjugated Hib vaccines produced &gt;90% protection in infants after a multidose series. After the initial Hib conjugate vaccines were licensed, subsequent formulations were licensed based on noninferior antibody responses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration:  Antibody concentrations exceeding 0.15 mcg/mL correlate with clinical protection from disease. Antibody concentrations exceeding 1 mcg/mL correlate with prolonged protection from disease, generally implying several years of protection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323178\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Hiberix Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg (1): $12.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Pedvax HIB Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mcg/0.5 mL (0.5 mL): $31.33</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178245\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Act-HIB (BE, BG, BR, CL, CN, DK, EE, FR, GR, IL, KR, PE, PK, PY, SE, UY);</li>\n      <li>Hiberix (AU, SI);</li>\n      <li>HIBest (FR, IN);</li>\n      <li>HibTITER (AE, AT, BH, CY, DE, EG, FI, GB, HN, IL, IQ, IR, IT, JO, KW, LB, LY, NZ, OM, QA, SA, SY, YE);</li>\n      <li>Pedvax HIB (BR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ActHIB (Haemophilus b conjugate vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briere EC, Rubin L, Moro P, Cohn A, Clark T, Messonnier N; Division of Bacterial Diseases; National Center for Immunization and Respiratory Diseases; CDC. Prevention and control of <i>Haemophilus influenzae</i> type b disease; recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2014;63(RR-01):1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-drug-information/abstract-text/24572654/pubmed\" target=\"_blank\" id=\"24572654\">24572654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Licensure of a <i>Haemophilus influenzae</i> type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. <i>MMWR Morb Mortal Wkly Rep</i>. 2009;58(36):1008-1009. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-drug-information/abstract-text/19763078/pubmed\" target=\"_blank\" id=\"19763078\">19763078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hiberix (Haemophilus B conjugate vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017; 66(5):136-138. doi: 10.15585/mmwr.mm6605e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    PedvaxHIB (Haemophilus B conjugate vaccine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc. December 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pisacane A, Continisio P, Palma O, et al, &quot;Breastfeeding and Risk for Fever After Immunization,&quot; <i>Pediatrics</i>, 2010, 125(6):e1448-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-drug-information/abstract-text/20478932/pubmed\" target=\"_blank\" id=\"20478932\">20478932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8511 Version 114.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178251\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178252\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F178262\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13361407\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F178258\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897418\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897419\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178235\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F178221\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734115\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F178238\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F178236\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F49748540\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178228\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178241\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178225\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299433\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178229\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178232\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F178244\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16570862\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13908724\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178224\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F25306341\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323178\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178245\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8511|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=haemophilus-influenzae-type-b-conjugate-vaccine-patient-drug-information\" class=\"drug drug_patient\">Haemophilus influenzae type b conjugate vaccine: Patient drug information</a></li><li><a href=\"topic.htm?path=haemophilus-influenzae-type-b-conjugate-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Haemophilus influenzae type b conjugate vaccine: Pediatric drug information</a></li></ul></div></div>","javascript":null}